Karn, T., Meissner, T., Weber, K. E., Solbach, C., Denkert, C., Engels, K., . . . Loibl, S. (2020). A small hypoxia signature predicted pCR response to bevacizumab in the neoadjuvant GeparQuinto breast cancer trial. Clinical cancer research, 26(8), . https://doi.org/10.1158/1078-0432.CCR-19-1954
Chicago-Zitierstil (17. Ausg.)Karn, Thomas, et al. "A Small Hypoxia Signature Predicted PCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial." Clinical Cancer Research 26, no. 8 (2020). https://doi.org/10.1158/1078-0432.CCR-19-1954.
MLA-Zitierstil (9. Ausg.)Karn, Thomas, et al. "A Small Hypoxia Signature Predicted PCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial." Clinical Cancer Research, vol. 26, no. 8, 2020, https://doi.org/10.1158/1078-0432.CCR-19-1954.